Brokerages Set Certara, Inc. (NASDAQ:CERT) Price Target at $17.79

Certara, Inc. (NASDAQ:CERT) has been given an average recommendation of “Hold” by the nine research firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $17.79.

Several equities analysts have recently weighed in on CERT shares. UBS Group lowered their price target on Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Robert W. Baird dropped their target price on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. KeyCorp cut their price target on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Barclays dropped their price objective on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Finally, JMP Securities reiterated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th.

Institutional Trading of Certara

Institutional investors and hedge funds have recently modified their holdings of the company. Mubadala Investment Co PJSC bought a new position in Certara in the 4th quarter worth $169,135,000. Wasatch Advisors LP boosted its stake in shares of Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after acquiring an additional 932,598 shares during the period. Geneva Capital Management LLC grew its position in shares of Certara by 15.1% during the first quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after purchasing an additional 579,349 shares in the last quarter. Clearbridge Investments LLC raised its stake in Certara by 0.8% during the 1st quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock valued at $74,617,000 after purchasing an additional 32,846 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after purchasing an additional 273,095 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Price Performance

Shares of NASDAQ:CERT opened at $11.80 on Wednesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -30.26, a price-to-earnings-growth ratio of 5.71 and a beta of 1.52. The business has a 50-day simple moving average of $14.04 and a two-hundred day simple moving average of $15.94. Certara has a fifty-two week low of $11.65 and a fifty-two week high of $19.87.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share. On average, analysts expect that Certara will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.